Genomics

Pierian® and P4 Diagnostix® Collaborate

Pierian

Pierian®, a global leader in advanced clinical genomics technology and services, is pleased to announce an exciting partnership with P4 Diagnostix®, a leading-edge network of nationally recognized laboratories. Now physician-owned laboratories (POLs) that specialize in urology, gastroenterology, or women’s health, can add next-generation sequencing (NGS) testing for hereditary cancer to their routine diagnostic practice.

Lowering the Barrier for In-House NGS Testing for POLs

Physician groups are eager to expand their in-house testing modalities to include advanced molecular testing. However, challenges such as clinical validation of NGS assays, technical assessments, overhead costs for additional headcount, and navigating the dynamic insurance reimbursement environment can pose significant challenges to deploying NGS in clinical practice.

Combining Pierian’s rich expertise in clinical next generation sequencing and P4’s long history of establishing POLs helps to reduce those barriers. Joint customers of Pierian and P4 will have access to several enabling services such as technical assessment consultation, enhanced validation services, and clinical sample procurement to support workflow design and implementation of NGS. As a result, the POLs will be ready for operation swiftly and efficiently enabling their physicians to provide the most efficacious therapies available for their patients.

“Our collaboration with P4 will help more physician-owned laboratories internalize clinical NGS, increasing patient access to testing and actionable results,” states Lindsay Mateo, Chief Business Officer at Pierian. “We are thrilled to expand our relationship with P4 as they are an industry leader that continues to positively impact the clinician experience and patient outcomes.”

Brett Reilly, Chief Commercial Officer at P4 said, “Being able to partner with Pierian allows us to offer our clients access to the latest technology and an extensive knowledgebase of clinically relevant data. Offering NGS testing and support services will empower our clients to deliver personalized therapy through more precise treatment pathways. This leads to better patient care and improved outcomes for patients with these disease states.”

Learn More:Visit Pierian and P4 Diagnostix at booth #107 from Nov. 10-12 at the Large Urology Group Practice Association (LUGPA) Annual Conference in Chicago, IL.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Business Wire

Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 18 newsrooms worldwide to meet the needs of communications professionals and news media.

Related posts

NeoGenomics Launches c-MET CDx Assay

Business Wire

Genomic Vision: 2021 Annual Results

Business Wire

New CRISPR/Cas9 license agreement for ERS Genomics and Cytosurge

PR Newswire